Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A monoclonal antibody that specifically binds to the constant region 1 of the human T-cell receptor beta chain (TRBC1). It is most widely known as clone JOVI-1 and is used for the detection of TRBC1-positive T-cell clones via flow cytometry. Its main application is in diagnosing T-cell malignancies (such as cutaneous T-cell lymphoma and other TCRαβ-positive T-cell neoplasms) by identifying clonal T-cell populations, exploiting the mutually exclusive expression of TRBC1 or TRBC2 on T-cells. This antibody is not only a diagnostic reagent but is also being explored as the targeting component in immunotherapeutics, including antibody-drug conjugates and bispecific antibodies for selective depletion of malignant T-cells while sparing much of the normal T-cell repertoire. The JOVI-1 antibody is highly selective for TRBC1, enabling its use in sophisticated diagnostic and therapeutic applications[1][2][7][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on t-cell receptor constant beta-1 chain antibody.